In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
The in-vitro activity of PD 117558, a new quinolone antimicrobial agent, was compared to that of four other quinolones, imipenem and ceftazidime against a variety of Gram-positive and Gram-negative isolates from cancer patients. PD 117558 was found to have a broad antimicrobial spectrum with excellent activity against all Gram-positive isolates (including methicillin-resistant Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus faecalis and Group JK-corynebacteria). It was also extremely active against Gram-negative bacilli with the exception of Pseudomonas aeruginosa against which ciprofloxacin was more active. Fleroxacin was slightly less active and S-25930 and S-25932 considerably less active than PD 117558. PD 117558 also had lower minimal inhibitory concentrations for most organisms tested than either imipenem or ceftazidime.
Rolston
K V
KV
Department of Medical Specialities, University of Texas M.D. Anderson Cancer Center, Houston 77030.
LeBlanc
B
B
Gooch
G
G
Ho
D H
DH
Bodey
G P
GP
D042462:4-Quinolones; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000150:complications / Q000382:microbiology*; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000150:complications*; D015363:Quinolones
D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C060016:PD 117588